Skip Navigation


Nucleic Acids Research Advance Access originally published online on March 5, 2007
Nucleic Acids Research 2007 35(7):e49; doi:10.1093/nar/gkm053
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (585K) Freely available
Right arrow Screen PDF (375K) Freely available
Right arrowOA All Versions of this Article:
35/7/e49    most recent
gkm053v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Morris, M. C.
Right arrow Articles by Divita, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morris, M. C.
Right arrow Articles by Divita, G.
Related Collections
Right arrow Targeted inhibition of gene function
Right arrow DNA transfer
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2007, Vol. 35, No. 7 e49
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Methods Online

A non-covalent peptide-based carrier for in vivo delivery of DNA mimics

May C. Morris1, Edwige Gros1, Gudrun Aldrian-Herrada1, Michael Choob2, John Archdeacon2, Frederic Heitz1 and Gilles Divita1,*

1Centre de Recherches en Biochimie Macromoléculaire, Department of Molecular Biophysics and Therapeutics, FRE-2593 CNRS, 1919 Route de Mende, 34293 Montpellier, France and 2Active Motif, Carlsbad, California, USA

*To whom correspondence should be addressed. Tel: +33 04 67 61 33 92; Fax: +33 04 67 52 15 59; Email: gilles.divita{at}crbm.cnrs.fr

Received October 4, 2006. Revised January 16, 2007. Accepted January 17, 2007.

The dramatic acceleration in identification of new nucleic-acid-based therapeutic molecules has provided new perspectives in pharmaceutical research. However, their development is limited by their poor cellular uptake and inefficient trafficking. Here we describe a short amphipathic peptide, Pep-3, that combines a tryptophan/phenylalanine domain with a lysine/arginine-rich hydrophilic motif. Pep-3 forms stable nano-size complexes with peptide-nucleic acid analogues and promotes their efficient delivery into a wide variety of cell lines, including primary and suspension lines, without any associated cytotoxicity. We demonstrate that Pep-3-mediated delivery of antisense-cyclin B1-charged-PNA blocks tumour growth in vivo upon intratumoral and intravenous injection. Moreover, we show that PEGylation of Pep-3 significantly improves complex stability in vivo and consequently the efficiency of antisense cyclin B1 administered intravenously. Given the biological characteristics of these vectors, we believe that peptide-based delivery technologies hold a true promise for therapeutic applications of DNA mimics.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
T. Shiraishi, R. Hamzavi, and P. E. Nielsen
Subnanomolar antisense activity of phosphonate-peptide nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells
Nucleic Acids Res., August 1, 2008; 36(13): 4424 - 4432.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.